Back to discover
Drug

Relatlimab

Approved medicine
ClassLymphocyte activation gene 3 protein inhibitorResearchOngoing clinical research

Also known as Opdualag.

RxNorm2596773ChEMBLCHEMBL3990044UNIIAF75XOF6W3
1
Research papers
20
Active clinical trials
LAG3
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events

Clinical trial2026-08-24Results expected Q2 2027 · ClinicalTrials.gov

A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)

Clinical trial2026-08-19Results expected Q2 2029 · ClinicalTrials.gov

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Clinical trial2026-08-11Results expected Q3 2030 · ClinicalTrials.gov

A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Clinical trial2026-08-10Results expected Q2 2029 · ClinicalTrials.gov

Molecular Analysis for Therapy Choice (MATCH)

Clinical trial2026-08-04Results expected Q4 2026 · ClinicalTrials.gov

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Clinical trial2026-07-29Results expected Q3 2029 · ClinicalTrials.gov

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Clinical trial2026-07-16Results expected Q3 2028 · ClinicalTrials.gov

A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Clinical trial2026-07-15Status changed to Active, not recruiting · ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Clinical trial2026-06-23Results expected Q3 2030 · ClinicalTrials.gov

A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer

Clinical trial2026-06-23Results expected Q4 2027 · ClinicalTrials.gov

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Clinical trial2026-06-18Results posted · ClinicalTrials.gov

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Research2022-10-26Nature

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Relatlimab
Aliases & brands
Opdualag
RxNorm CUI
2596773
ChEMBL ID
CHEMBL3990044
UNII
AF75XOF6W3
Primary mechanism
Lymphocyte activation gene 3 protein inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Lymphocyte activation gene 3 protein
LAG3 · P18627
INHIBITORLymphocyte activation gene 3 protein inhibitor

Clinical trials

47 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
47
registered trials across all phases
LATEST COMPLETION 2026
20
Active studies
9
Recruiting
4
Late-stage (III+)
18
Completed
9
Discontinued
PHASE DISTRIBUTIONn = 47
Phase 17Phase 1 / 29Phase 227Phase 2 / 32Phase 31Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multi-center Trial Evaluating the ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab for Advanced Melanoma

RecruitingPH IVNYU Langone Healthn=902031

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

RecruitingPH IIIKey trialBristol-Myers Squibbn=1,0002032

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Active, not recruitingPH II/IIIBristol-Myers Squibbn=7142030

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

RecruitingPH II/IIINational Cancer Institute (NCI)n=9922030

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

CompletedPH IIBristol-Myers Squibbn=4682026

A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma

CompletedPH IIJose Lutzky, MDn=272026

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

CompletedPH IIBristol-Myers Squibbn=2662025

A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma

CompletedPH I/IIBristol-Myers Squibbn=832025

A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

CompletedPH I/IIBristol-Myers Squibbn=2292025

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

CompletedPH I/IIBristol-Myers Squibbn=1,4822025

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Nature · 2022 · 240 cites
Recent papers

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Nature · 2022 · 240 cites
Major research themes3
Melanoma1Neoadjuvant Therapy1Nivolumab1
Journals, researchers & institutions
Top journals
  • Nature1
Leading researchers
  • Allison JP1
  • Amaria RN1
  • Ariyan C1
  • Bartlett EK1
  • Bello D1
  • Betof-Warner A1
  • Burton EM1
  • Busam K1
Leading institutions
free-text, unnormalised
  • Memorial Sloan Kettering Cancer Center1
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College1
  • The University of California San Francisco1
  • The University of Texas MD Anderson Cancer Center1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Nivolumab

Studied across the same disease area as Relatlimab in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials